CRTHF (CARsgen Therapeutics Holdings) LT-Debt-to-Total-Asset: 0.04 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRTHF CARsgen Therapeutics Holdings Ltd CRTHF
21 GF Score
Price $1.91
! 3 Warning Signs
View Full Analysis

What is CARsgen Therapeutics Holdings LT-Debt-to-Total-Asset?

CARsgen Therapeutics Holdings CRTHF 21 LT-Debt-to-Total-Asset is 0.04 as of Dec. 2025. GuruFocus rates CRTHF with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CARsgen Therapeutics Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.04.

CARsgen Therapeutics Holdings's long-term debt to total assets ratio declined from Dec. 2024 (0.08) to Dec. 2025 (0.04). It may suggest that CARsgen Therapeutics Holdings is progressively becoming less dependent on debt to grow their business.

CARsgen Therapeutics Holdings  (OTCPK:CRTHF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CARsgen Therapeutics Holdings LT-Debt-to-Total-Asset Related Terms

CARsgen Therapeutics Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for CARsgen Therapeutics Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARsgen Therapeutics Holdings LT-Debt-to-Total-Asset Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.03 0.04 0.03 0.08 0.04

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.09 0.08 0.04 0.04
CRTHF
21GF Score
CARsgen Therapeutics Holdings Ltd CRTHF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CARsgen Therapeutics Holdings LT-Debt-to-Total-Asset Calculation

CARsgen Therapeutics Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=6.863/183.459
=0.04

CARsgen Therapeutics Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=6.863/183.459
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.04 mean?
CARsgen Therapeutics Holdings (CRTHF) has a LT-Debt-to-Total-Asset of 0.04 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CARsgen Therapeutics Holdings and its competitors.
Is CARsgen Therapeutics Holdings' LT-Debt-to-Total-Asset too high?
CARsgen Therapeutics Holdings' current LT-Debt-to-Total-Asset is 0.04. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' LT-Debt-to-Total-Asset compare to VRTX and REGN?
CARsgen Therapeutics Holdings' LT-Debt-to-Total-Asset of 0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CARsgen Therapeutics Holdings and its competitors. CARsgen Therapeutics Holdings's current LT-Debt-to-Total-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (CRTHF) has a current LT-Debt-to-Total-Asset of 0.04. The current LT-Debt-to-Total-Asset is 0.04. CARsgen Therapeutics Holdings' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (CRTHF), the current LT-Debt-to-Total-Asset is 0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARsgen Therapeutics Holdings Business Description

Other Exchanges 02171:Hong Kong
Address No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
21GF Score

Get the complete analysis for CRTHF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.91
Price